The U.S. Food and Drug Administration (FDA) has approved a new biologic medication, lebrikizumab-lbkz (Ebglyss), for moderate to severe atopic dermatitis. This treatment is available to people aged 12 and older who aren’t getting enough relief from prescription topical treatments, like creams or ointments. In studies, 38 percent of people who used this drug saw clear or almost clear skin after 16 weeks, compared to 12 percent who took a placebo (an inactive treatment). Also, 43 percent of people taking lebrikizumab-lbkz said their itch improved by week 16, with some feeling better as soon as two weeks in.

Lebrikizumab-lbkz is a biologic, a type of medication that targets specific proteins in the body. It works by blocking a protein called interleukin (IL)-13, which is known to cause eczema inflammation.

The drug is generally taken as a monthly shot after an initial period of more frequent doses.

According to the manufacturer, Lilly, the most common side effects include eye and eyelid inflammation, swelling and itching, injection site reactions, and shingles.

Are Biologics Right for You?

Some people with moderate to severe atopic dermatitis don’t find lasting relief from symptoms like itching with topical treatments. Lebrikizumab-lbkz offers a new treatment option that targets only IL-13, unlike other medicines that block multiple inflammation proteins.

As with all treatments, biologics can cause side effects, including a higher risk of infections. Talk with your health care provider about whether your current treatment is working well and if you experience side effects. They can help you find a plan that suits your individual needs.

Are you curious about biologics? Read about one MyEczemaTeam member’s experiences.

Find Your Team

On MyEczemaTeam, the social network for people living with eczema and their loved ones, members come together to ask questions, give advice, and share their stories with others who understand life with eczema.

Have you tried biologic treatments for your eczema? How has it affected your symptoms? Share your thoughts and experience in the comments below, start a discussion on your Activities page, or connect with like-minded members in Groups.